약물유전체학 기술 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Pharmacogenomics Technology Market size is expected to reach USD 18.45 Billion in 2034 from USD 8.77 Billion (2025) growing at a CAGR of 8.62% during 2026-2034.

The Global Pharmacogenomics Technology Market is witnessing rapid growth as personalized medicine becomes central to modern healthcare strategies. Increasing awareness about genetic variability in drug response is encouraging healthcare systems to integrate genomic testing into routine treatment protocols. Advances in sequencing technologies and bioinformatics tools have reduced testing costs and improved data accuracy, strengthening adoption across clinical and research settings.

Key drivers include rising incidences of chronic diseases, growing demand for targeted therapies, and government initiatives promoting precision medicine programs. Pharmaceutical companies are leveraging pharmacogenomic insights to optimize drug development and minimize adverse drug reactions. Additionally, expanding clinical trials and investments in genomic research are reinforcing market expansion across developed and developing economies.

Future prospects remain highly promising as AI-driven analytics and next-generation sequencing platforms reshape genomic interpretation. Integration of pharmacogenomics into electronic health records will streamline clinical decision-making. As reimbursement frameworks improve and regulatory pathways become clearer, broader implementation in routine clinical practice is expected to unlock significant growth potential in the coming years.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Therapeutic Area

• Oncology
• Neurological Disorders
• Cardiovascular Disease
• Immunological Disorders
• Infectious Diseases
• Others

By Technology

• PCR
• In-situ Hybridization
• Immunohistochemistry
• Sequencing
• Others

COMPANIES PROFILED

• QIAGEN, GE HealthCare, Agilent Technologies Inc, FHoffmann La Roche Ltd, Foundation Medicine Inc, Thermo Fisher Scientific Inc, Oxford Nanopore Technologies plc, Twist Bioscience, Leica Biosystems Nussloch GmbH, Pfizer Inc, Abbott Laboratories
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PHARMACOGENOMICS TECHNOLOGY MARKET: BY THERAPEUTIC AREA 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Therapeutic Area
• 4.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Neurological Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Cardiovascular Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Immunological Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PHARMACOGENOMICS TECHNOLOGY MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Technology
• 5.2. PCR Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. In-situ Hybridization Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Immunohistochemistry Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Sequencing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PHARMACOGENOMICS TECHNOLOGY MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Therapeutic Area
  • 6.2.2 By Technology
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Therapeutic Area
  • 6.3.2 By Technology
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Therapeutic Area
  • 6.4.2 By Technology
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Therapeutic Area
  • 6.5.2 By Technology
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Therapeutic Area
  • 6.6.2 By Technology
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL PHARMACOGENOMICS TECHNOLOGY INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 QIAGEN
  • 8.2.2 GE HealthCare
  • 8.2.3 Agilent Technologies Inc
  • 8.2.4 F.A¢a,A¯Hoffmann La Roche Ltd
  • 8.2.5 Foundation Medicine Inc
  • 8.2.6 Thermo Fisher Scientific Inc
  • 8.2.7 Oxford Nanopore Technologies Plc
  • 8.2.8 Twist Bioscience
  • 8.2.9 Leica Biosystems Nussloch GmbH
  • 8.2.10 Pfizer Inc
  • 8.2.11 Abbott Laboratories